Name | Number of supported studies  | Average coverage | |
|---|---|---|---|
| adipocyte | 7 studies | 22% ± 4% | |
| natural killer cell | 4 studies | 21% ± 6% | |
| astrocyte | 4 studies | 31% ± 13% | |
| endothelial cell of lymphatic vessel | 3 studies | 24% ± 3% | |
| CD16-positive, CD56-dim natural killer cell, human | 3 studies | 27% ± 9% | |
| CD8-positive, alpha-beta T cell | 3 studies | 28% ± 2% | |
| epithelial cell | 3 studies | 25% ± 6% | |
| CD8-positive, alpha-beta memory T cell | 3 studies | 19% ± 1% | |
| macrophage | 3 studies | 23% ± 1% |
Insufficient scRNA-seq data for expression of PRR5 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| prostate | 100% | 1798.84 | 245 / 245 | 99% | 11.72 | 499 / 502 |
| stomach | 100% | 662.36 | 358 / 359 | 98% | 10.60 | 281 / 286 |
| kidney | 100% | 1667.98 | 89 / 89 | 98% | 6.89 | 882 / 901 |
| breast | 100% | 1912.27 | 459 / 459 | 98% | 7.81 | 1092 / 1118 |
| bladder | 100% | 1307.67 | 21 / 21 | 97% | 9.00 | 490 / 504 |
| lung | 100% | 682.88 | 576 / 578 | 97% | 8.10 | 1125 / 1155 |
| pancreas | 98% | 571.14 | 322 / 328 | 99% | 8.49 | 176 / 178 |
| ovary | 99% | 902.12 | 179 / 180 | 97% | 6.35 | 418 / 430 |
| thymus | 100% | 967.03 | 652 / 653 | 96% | 5.86 | 580 / 605 |
| liver | 100% | 1762.41 | 226 / 226 | 96% | 6.43 | 388 / 406 |
| uterus | 99% | 866.97 | 169 / 170 | 94% | 9.17 | 433 / 459 |
| intestine | 92% | 926.72 | 889 / 966 | 99% | 11.30 | 523 / 527 |
| skin | 99% | 913.51 | 1784 / 1809 | 91% | 9.49 | 428 / 472 |
| esophagus | 88% | 630.27 | 1268 / 1445 | 100% | 9.73 | 183 / 183 |
| brain | 87% | 973.86 | 2294 / 2642 | 85% | 4.51 | 601 / 705 |
| adrenal gland | 88% | 383.44 | 227 / 258 | 56% | 3.94 | 128 / 230 |
| adipose | 100% | 1790.98 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| eye | 0% | 0 | 0 / 0 | 100% | 18.91 | 80 / 80 |
| spleen | 100% | 4470.98 | 241 / 241 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 100% | 10.25 | 1 / 1 |
| tonsil | 0% | 0 | 0 / 0 | 98% | 8.27 | 44 / 45 |
| peripheral blood | 97% | 1289.49 | 902 / 929 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 86% | 7.23 | 25 / 29 |
| heart | 57% | 241.37 | 494 / 861 | 0% | 0 | 0 / 0 |
| blood vessel | 46% | 233.83 | 610 / 1335 | 0% | 0 | 0 / 0 |
| muscle | 6% | 17.37 | 47 / 803 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| GO_0031669 | Biological process | cellular response to nutrient levels |
| GO_0051897 | Biological process | positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0043066 | Biological process | negative regulation of apoptotic process |
| GO_0007010 | Biological process | cytoskeleton organization |
| GO_0001934 | Biological process | positive regulation of protein phosphorylation |
| GO_0030307 | Biological process | positive regulation of cell growth |
| GO_0038203 | Biological process | TORC2 signaling |
| GO_0043491 | Biological process | phosphatidylinositol 3-kinase/protein kinase B signal transduction |
| GO_0031932 | Cellular component | TORC2 complex |
| GO_0005829 | Cellular component | cytosol |
| GO_0005515 | Molecular function | protein binding |
| Gene name | PRR5 |
| Protein name | Proline-rich protein 5 (Protein observed with Rictor-1) (Protor-1) Proline rich 5 HCG2039433, isoform CRA_a (Proline rich 5) |
| Synonyms | hCG_2039433 PROTOR1 PP610 |
| Description | FUNCTION: Subunit of mTORC2, which regulates cell growth and survival in response to hormonal signals. mTORC2 is activated by growth factors, but, in contrast to mTORC1, seems to be nutrient-insensitive. mTORC2 seems to function upstream of Rho GTPases to regulate the actin cytoskeleton, probably by activating one or more Rho-type guanine nucleotide exchange factors. mTORC2 promotes the serum-induced formation of stress-fibers or F-actin. mTORC2 plays a critical role in AKT1 'Ser-473' phosphorylation, which may facilitate the phosphorylation of the activation loop of AKT1 on 'Thr-308' by PDK1 which is a prerequisite for full activation. mTORC2 regulates the phosphorylation of SGK1 at 'Ser-422'. mTORC2 also modulates the phosphorylation of PRKCA on 'Ser-657'. PRR5 plays an important role in regulation of PDGFRB expression and in modulation of platelet-derived growth factor signaling. May act as a tumor suppressor in breast cancer. . |
| Accessions | ENST00000336985.11 [P85299-1] ENST00000403581.5 [P85299-5] ENST00000457960.5 ENST00000403696.5 ENST00000617066.4 [P85299-4] ENST00000432186.5 ENST00000611394.4 [P85299-3] E9PH80 ENST00000431834.5 G3V0G2 ENST00000006251.11 [P85299-3] ENST00000432916.5 B1AHG4 F8WEZ7 P85299 ENST00000624862.3 [P85299-4] B1AHG3 |
